Vanda Pharmaceuticals Inc (NASDAQ: VNDA) kicked off on Tuesday, down -3.97% from the previous trading day, before settling in for the closing price of $5.29. Over the past 52 weeks, VNDA has traded in a range of $3.30-$6.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 1.11% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -1300.00%. With a float of $55.19 million, this company’s outstanding shares have now reached $57.53 million.
In an organization with 203 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 90.95%, operating margin of -17.84%, and the pretax margin is -6.57%.
Vanda Pharmaceuticals Inc (VNDA) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Vanda Pharmaceuticals Inc is 5.32%, while institutional ownership is 75.42%. The most recent insider transaction that took place on Jul 29 ’24, was worth 13,327. In this transaction SVP, CFO & Treasurer of this company sold 2,251 shares at a rate of $5.92, taking the stock ownership to the 228,763 shares. Before that another transaction happened on Jul 29 ’24, when Company’s Officer proposed sale 2,251 for $5.92, making the entire transaction worth $13,327.
Vanda Pharmaceuticals Inc (VNDA) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported 0.03 earnings per share (EPS), higher than consensus estimate (set at -0.13) by 0.16. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1300.00% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 36.10% during the next five years compared to -37.98% drop over the previous five years of trading.
Vanda Pharmaceuticals Inc (NASDAQ: VNDA) Trading Performance Indicators
Take a look at Vanda Pharmaceuticals Inc’s (VNDA) current performance indicators. Last quarter, stock had a quick ratio of 4.67. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.63.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.19, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach 0.27 in one year’s time.
Technical Analysis of Vanda Pharmaceuticals Inc (VNDA)
Let’s dig in a bit further. During the last 5-days, its volume was 0.43 million. That was inferior than the volume of 1.5 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 23.97%. Additionally, its Average True Range was 0.19.
During the past 100 days, Vanda Pharmaceuticals Inc’s (VNDA) raw stochastic average was set at 39.60%, which indicates a significant increase from 6.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 31.98% in the past 14 days, which was lower than the 74.17% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.59, while its 200-day Moving Average is $4.69. However, in the short run, Vanda Pharmaceuticals Inc’s stock first resistance to watch stands at $5.27. Second resistance stands at $5.45. The third major resistance level sits at $5.56. If the price goes on to break the first support level at $4.98, it is likely to go to the next support level at $4.87. Assuming the price breaks the second support level, the third support level stands at $4.69.
Vanda Pharmaceuticals Inc (NASDAQ: VNDA) Key Stats
The company with the Market Capitalisation of 296.11 million has total of 58,198K Shares Outstanding. Its annual sales at the moment are 192,640 K in contrast with the sum of 2,510 K annual income. Company’s last quarter sales were recorded 50,470 K and last quarter income was -4,520 K.
